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Objective:The objective of the present study is to formulate colon targeted matrix tablets 
containing Solenostemma argel extract using guar gum alone or in combination with either 
HPMC K15M, with Eudragit S100, or with both them.  
Methods:The Hargel colon targeted matrix tablets were prepared by wet granulation method. 
The prepared matrix tablets were evaluated for the weight variation, hardness, friability, and in-
vitro drug release study in three different media.  
Results:The formulations showed compliance with pharmacopial standards except that 
containing guar gum alone. There was nointeraction between drug, polymer and other excipients. 
It was confirmed by FTIR studies. Among the formulations,GHE2 (i.e. containing triple polymer 
mixture) showed goodresults in release retardation and other physicochemical properties of 
matrix tablets when compare to other formulations. The optimum formulation(GHE2) was stable 
when it was stored at 45
0
/75% RH for 3 months. 
Conclusion:The formulation GHE2 was considered the most suitable formula for targeted the 
colon. 
KEYWORDS: Colon Targeted Matrix Tablets, Guar Gum, HPMC K15M, Eudragit S100, 
Hargel Extract, Colorectal Cancer. 
 
1. Introduction 
Colon delivery systems are potential for delivering various drugs to treat the local 
diseases for colon including colon cancer 
[1]
. Guar gum is reported to be potential carrier for 
colon specific drug delivery, due to its drug release retarding property and susceptibility to 
microbial degradation in the large intestine 
[2-4]
. It is the best polymer for control release matrix 
tablets but it produces burst effect for water-soluble drugs in starting hrs. In order to minimize it 
a combination of guar gum with other polymers such as HPMC K15M or/and Eudragit S100 is 
necessary. Indeed, a combination of these polymers is an approach that may allow formulators to 
  
develop colon targeting dosage form that may exhibits performance improvements over the 
individual polymer components. It provides a neat and smooth means of combining desirable 
properties of different polymers
[5, 6]
. Recently, a lot of studies reported that a combination of 
different gums or polymers to increase matrix viscosity and optimize release often leads to syn-
ergistic interactions 
[7, 8]
.To achieve colon delivery, preparation of matrix tablets is simple 
method when compared to other methods like tablets coated with different polymers and 
chemical conjugation of drug 
[9]
. 
Colorectal cancer is one of the highest incidence and mortality cancers worldwide
[10]
. In 
Sudan, colorectal cancer is the fifth most commonly diagnosed cancer
[11]
. The serious side 
effects of chemotherapeutics and the resistance developed by tumor cells in addition to 
recurrence and metastasis highlightened the urge need for search to find more safe and efficient 
therapies
[12, 13]
. Plant derived products have been valuable source for the discovery and 
development of unique anticancer drugs, which target multiple pathways in cancer cells and are 
associated with limited or no side effects
[14, 15]
.Solenostemma argel is one of the most commonly 
used medicinal plants in Sudan. Many of scientific studies have been carried out reporting that 
the extracts of Solenostemma argel possess various antitumor activities
[16-19]
.The main objective 
of this study is to formulate, and evaluate a novel matrix tablet using the methanol extract of 
Solenostemma argel (Hargel) leaves to target a colon, for provide effective, and safe therapy for 
colorectal cancer. 
 
2. Materials and Methods 
2.1. Materials  
Hargel dried leaves were obtained from local market in Khartoum. Guar gum was 
procured from (Gitaf, Sudan). HPMC K15M was obtained from (Dow Chemical, Michigan, 
USA).Eudragit S100 was received from (Evonik, Germany).Lactose monohydrate was obtained 
from (Breckland scientific supplier, UK).MCC PH 101and Talc were obtained from (A Johnson 
Matthy, UK).PVP K30and Magnesium stearatewere obtained from (Techno pharmchem, 
India).All other chemicals used wereof analytical grade. 
2.2. Methods  
2.2.1. Formulation of Hargel Colon Targeted Matrix Tablets 
2.2.1.1.Preparation of Solenostemma argel (Hargel) Extract 
Hargel dried leaves were cleaned from other parts of the plant and crushed by hand, then 
1 kg of hargel dried leaves exhaustively extracted with 80% methanol in Soxhlet apparatus. The 
  
solvent was evaporated under reduced pressure using Rotary evaporator. The extract was 
maintained at 4 ᵒC and protect from light [20]. 
The methanolic extract of Solenostemma argel leaves was formulated as colon targeted 
matrix tablet by wet granulation method using different polymers include Guar gum, HPMC 
K15M, and Eudragit S100 in addition to other excipients such as MCC as filler, PVP K30 as 
binder, Mg stearate as lubricant, and Talc as glidant. 
2.2.1.2.Compatibility Study of Hargel Extract and Polymers  
The infrared spectra of drug alone (Hargel extract), and granules of Hargel matrix tablet 
(G2, GH2, GE2, and GHE2) were recorded in range from 400 to 4000 cm
-1 
on FTIR to detect the 
drug-polymers interactions. The IR spectra for the test samples were obtained using KBr disk 
method using an FTIR spectrometer. The resultant spectra were compared for any possible 
changes in the peaks of the spectra 
[21]
. 
2.2.1.3.Preparation of Hargel Colon Targeted Matrix Tablets  
Weighed quantity of Hargel extract, Guar gum, HPMC K15M, Eudragit S100, and MCC 
were sieved and mixed properly in polybag for 15 minutes. A binder solution (PVP K30 in 
mixture of Isopropyl alcohol and water solution 3:1) was added to above blend to prepare a 
dough mass. The dough mass was granulated using a 14 mesh screen and the granules obtained 
were dried in oven at 80 
0
C for 2 hrs. The dried granules were passed through 20 # sieve. The 
dried granules were lubricated using talc and magnesium Stearate (2:1) for 5 minutes. The 
lubricated granules were compressed to tablets using a 12 mm concave single punch tablet 
machine (Korsch, Germany). Table 1 shows the compositions of Hargel colon targeted matrix 
tablet of 12 Formulae. 
2.2.2. Evaluation  
2.2.2.1.Evaluation of Granules 
2.2.2.1.1. Angle of repose  
The angle of repose was calculated using the following equation: 
tan θ = 
 
 
        
 Where,  
tan θ - tangent of angle 
r – Radius of base of the heap (cm) and  
h - Height of the heap (cm). 
2.2.2.1.2. Bulk and Tapped density  
To calculate the densities the following equations were used: 
 
  
Bulk density = 
                     
           
   
Tapped density = 
                     
             
 
2.2.2.1.3. Compressibility index 
Carr’s index was calculated according to equation given below: 
Carr’s index = 
               –            
              
  X 100 
2.2.2.1.4. Hausner’s ratio 
It is the ratio of tapped density to bulk density of the powder and measured by employing 
the following formula. 
Hausner’s ratio = 
              
            
 
 
2.2.2.2.Evaluation of Hargel Colon Targeted Matrix Tablets  
2.2.2.2.1. Weight variation test 
The weight variation test was analyzed by selecting twenty tablets randomly and average 
weights were determined. Then individual tablet weighed and compared with the average. The 
requirement met the (USP, 2016)
[22]
; if not more than two tablets differ from the average weight 
± 5% and no tablet differs in weight by double that percentage, the tablets will be accepted. 
2.2.2.2.2. Hardness test 
The resistance of tablets to shipping or breakage under conditions of storage, 
transportation, and handling before usage depends on its hardness. The hardness of tablet of each 
formulation was measured by Monsanto hardness tester. The hardness was measured in terms of 
kg/cm
2
.The test was conducted as per (USP, 2016)
[22]
. 
2.2.2.2.3. Friability test 
Friability is the measure of tablet strength. Erweka Friabilitor was used to perform the 
test. Twenty tablets were weighed accurately and placed in the tumbling apparatus that revolves 
at 25 rpm dropping the tablets through a distance of six inches with each revolution. After 4 
min., the tablets were weighed and the percentage loss in tablet weight was determined. 
Conventional compressed tablets that lose less than 0.5 to 1.0% of their weight are generally 
considered acceptable.The test was conducted as per (USP, 2016)
[22]
. 
2.2.2.2.4. Thickness test 
Thickness was calculated using vernier caliper. Ten tablets from each formula were used, 
and average values were calculated. The test was conducted as per (USP, 2016)
[22]
. 
2.2.2.2.5. In – Vitro drug release study 
  
The drug release studies were carried out using USP dissolution test apparatus I (basket) 
at 50 rpm and 37 ± 0.5°C temperature using 500 ml of 0.1N HCl pH 1.2 (simulated gastric fluid) 
a dissolution medium in the first 2 h of study as the average gastric emptying time is about 2 h. 
At the end of 2 h, the dissolution media was replaced with 500 ml of phosphate buffer pH 6.8 
(simulated intestinal fluid) and drug release study was continued for another 3 h as the average 
small intestine transit time is about 3 h (i.e., total 5 h). At the end of 5 h, the dissolution media 
was replaced with 500 ml of phosphate buffer pH 7.4 (simulated colonic fluid) and drug release 
study was continued for next 19 h. 10 ml samples were withdrawn at regular time intervals and 
correspondingly replaced with fresh media. The amount of drug release was analyzed 
spectrophotometrically at λmax of 265 nm 
[23]
. 
2.2.3. Stability Study 
The best formulation was subjected to accelerated stability study according to ICH 
guidelines at temperature 45±20 C and 75±5% RH (Relative Humidity) for 3 months in stability 
chamber. At the end of each month, the physicochemical properties of tablets including 
organoleptic properties, average weight, hardness, friability, and dissolution were evaluated. 
2.2.4. Statistical Analysis 
The results obtained are expressed as a mean ± standard deviation calculated using 
Microsoft excel 2010 software. Statistical analysis was performed using SPSS version 20.0 for 
windows (SPSS Inc. Sep 2011). 
3. Results and Discussion  
3.1.Compatibility Study of Hargel Extract and Polymers 
Figures 1 – 5 display the IR spectra of physical mixture of hargel extract and guar gum 
(G2), physical mixture of hargel extract, guar gum and HPMC K15M (GH2), physical mixture of 
hargel extract, guar gum and Eudragit S100 (GE2), and physical mixture of hargel extract, guar 
gum, HPMC K15Mand Eudragit S100 (GHE2).From these Infrared spectra, it observes that 
hargel extract showed characteristic peaks at 3417.63 cm
-1





 (C=O bending), and 1290.29 cm
-1
 (C-N bending). Furthermore, there is 
not significant change between these peaks and peaks obtained in the spectra of each physical 
mixture of hargel extract with polymers used. Therefore, the hargel extract is compatible with all 
polymers used. 
3.2.Evaluation of Granules 
Table 2 shows the results of Angle of repose, Bulk density, Tapped density, Carr’s index, 
and Hausner’s ratio for granules of all formulae.The results of granules evaluation summarized 
  
in (Table 2) indicate good flow properties of prepared granules for all formulae. This is observed 




) which indicate good flow 
properties of prepared granules. According to table 2, the compressibility index values up to 20% 
and hausner’s ratio less than 1.25 indicate fair to good compressibility and flowability. 
 
3.3.Evaluation of Hargel Colon Targeted Matrix Tablets 
The colon targeted matrix tablets were prepared using guar gum alone, and in 
combination either with HPMC K15M, with Eudragit S100, or with both HPMC K15M and 
Eudragit S100. Thus, twelve formulations were prepared (Table 1). Table 3shows the results of 
weight variation test, hardness test, friability test, and thickness test for prepared hargel colon 
targeted matrix tablets of all formulae.The results indicate that the weight variation for different 
formulations is found to be within the pharmacopeia limit of 5% as per USP standard. Also, the 
thickness is uniform and reproducible. 
The results of hardness test demonstrated that matrices of guar gum alone (G1 – G4) 
failed in the test, this is attributed to the compaction properties of guar gum 
[24]
. However, the 
hardness is a parameter which can be related directly to the compression force used that causes 
decreasing in the powder volume due to elastic and/or plastic deformation and the degree of 
particle attrition behaviors of the particle-particle bonds in the powder mass 
[25]
. The hardness of 
the matrices containing a combination of guar gum either with HPMC K15M, with Eudragit 
S100, or with both them was found to be satisfactory and conformed to those given in 
pharmacopeia (USP, 2016). This indicates that incorporation of both HPMC K15M and Eudragit 
S100 to guar gum provides more mechanical strength for matrix tablets and, hence, resulted in 
successfully preparation of matrix tablets with a required hardness. 
The results of friability test revealed that matrices containing guar gum only (G1 – G4) 
failed in the test, this is due to their hardness which is extremely low. However, the friability was 
affected by the content of guar gum where it showed higher with the large quantity of guar gum 
[26]
.The friability of the matrices containing a combination of guar gum either with HPMC 
K15M, with Eudragit S100, or with both them was found to be reasonable and conformed to 
those given in pharmacopeia (USP, 2016).  
3.4.In–vitro drug release study 
The dissolution test was carried out for the twelve formulae using three different 
dissolution medium (0.1N HCl pH 1.2, phosphate buffer pH 6.8 and pH 7.4). The following 
results were obtained after carrying the dissolution test for 24 hours, by measuring drug release 
  
from matrix tablets at different time intervals (2, 5, 8, 12, 16, 20, and 24 hour). The results of the 
dissolution test for 12 formulae are shown in (Fig. 6). The results demonstrated that the matrix 
tablets retained their physical integrity up to 24 h of the dissolution study conducted without rat 
caecal content in the dissolution medium except that containing guar gum alone which are 
divided into two parts. Matrix tablets containing guar gum alone showed higher percent release 
compared to others which are containing polymer combinations.According to fig. 6, the percent 
of drug released from matrix tablets containing guar gum alone was ranged between 30 – 35.74% 
after 5 h, while it was ranged from 13.9 – 28.2%for matrix tablets containing the polymer 
combinations. However, the drug release rate from matrix tablets is dependent on the formation 
and viscosity of gel layer and its swelling or erosion rate 
[27]
. This result suggests that guar gum 
alone was unable to retard the drug release in the stomach and small intestine,while the matrices 
containing a polymer combinations could be retarded the drug release in stomach and small 
intestine and, hence, capable to deliver the drug (Hargel extract) to a colon. 
3.5. Stability study 
The results of accelerated stability study test for the best formula (GHE2) revealed that 
the matrix tablets retained their organoleptic and physicochemical characteristics, over three 
months of storage. Therefore, it could be considered stable according to the ICH guidelines. 
4. Conclusion 
The effective extract of S. argel can be successfully formulated as colon targeted matrix 
tablet by wet granulation method. The results suggest that matrix tablet containing a combination 
of guar gum with HPMC K15M and Eudragit S100 (GHE2) was most likely to provide targeting 
of drug (Hargel extract) for treatment colorectal cancer. 
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Figure 1: FT-IR spectrum of the methanolic extract of Solenostemma argel leaves 
 
 
Figure 2:  The compatibility between hargelleaf methanolic extract and guar gum 
  
 
Figure 3:  The compatibility between hargel leaf methanolic extract, guar gum, and HPMC  
 
 
Figure 4:  The compatibility between hargel leaf methanolic extract, guar gum, and Eudragit  
  
 
Figure 5:  The compatibility between hargel leaf methanolic extract, guar gum, HPMC, and Eudragit 
 
 
Figure 6:  In vitro drug release profile of hargel colon targeted matrix tablets of all formulae. 
 
Table 1: The Compositions of colon targeted matrix tablet 

































Hargel Extract (mg) 90 90 90 90 90 90 90 90 90 90 90 90 
Guar gum (mg) 90 180 180 180 90 180 90 90 180 90 90 180 
HPMC K15M (mg) - - - - 90 90 180 - - - 90 90 
Eudragit S100 (mg) - - - - - - - 90 90 180 90 90 
Lactose (mg) - - - 70 - - - - - - - - 
MCC (mg) 30 30 100 30 30 30 30 30 30 30 30 30 
PVP (mg) 18 18 18 18 18 18 18 18 18 18 18 18 
Talc (mg) 8 8 8 8 8 8 8 8 8 8 8 8 
Mg. Stearate (mg) 4 4 4 4 4 4 4 4 4 4 4 4 
G: Guar gum, GH: Guar gum + HPMC K15M, GE: Guar gum + Eudragit S100,  
GHE: Guar gum + HPMC K15M + Eudragit S100 
Table 2: Evaluation of granules of all formulate 
Formulation 
code 
Angle of repose Bulk density Tapped density Carr’s index 
Hausner’s 
ratio 
G1 33.24 ± 0.75 0.3774 ± 0.0071 0.4653 ± 0.0108 18.87 ± 0.36 1.23 ± 0.01 
G2 32.83 ± 0.94 0.3394 ± 0.0149 0.4112 ± 0.0130 17.47 ± 1.92 1.21 ± 0.03 
G3 31.67 ± 0.76 0.3509 ± 0.0062 0.4204 ± 0.0225 16.41 ± 2.97 1.20 ± 0.04 
G4 33.24 ± 0.75 0.3871 ± 0.0044 0.4695 ± 0.0224 17.43 ± 3.44 1.21 ± 0.05 
GH1 29.27 ± 1.10 0.3681 ± 0.0039 0.4584 ± 0.0162 19.63 ± 2.80 1.23 ± 0.03 
GH2 27.89 ± 0.40 0.4317 ± 0.0053 0.5088 ± 0.0152 15.11 ± 2.18 1.18 ± 0.03 
GH3 27.67 ± 1.26 0.3826 ± 0.0155 0.4584 ± 0.0162 16.55 ± 0.50 1.20 ± 0.01 
GE1 27.11 ± 0.47 0.3297 ± 0.0062 0.3871 ± 0.0044 14.82 ± 1.41 1.17 ± 0.02 
GE2 28.53 ± 0.06 0.3824 ± 0.0111 0.4446 ± 0.0099 14.00 ± 0.72 1.16 ± 0.01 
GE3 27.17 ± 1.04 0.3593 ± 0.0037 0.4138 ± 0.0049 13.17 ± 0.97 1.15 ± 0.01 
GHE1 25.15 ± 0.24 0.3410 ± 0.0066 0.3923 ± 0.0077 13.07 ± 0.89 1.15 ± 0.01 
GHE2 27.37 ± 2.14 0.3243 ± 0.0031 0.3705 ± 0.0069 12.44 ± 1.00 1.14 0.01 
G: Guar gum, GH: Guar gum + HPMC K15M, GE: Guar gum + Eudragit S100,  










Table 3: Evaluation of prepared hargel colon targeted matrix tablets of all formulae 
Formulation  
code 












(n=10) Weight variation 
Deviation 
(%) 
G1 242.3 ± 3.8 1.5 ± 1.4 1.18 ± 0.06 93.5 ± 2.85 1.82 ± 0.01 
G2 332.0 ± 0.7 1.1 ± 1.0 1.53 ± 0.12 87.2 ± 3.01 2.53 ± 0.03 
G3 402.5 ± 0.9 1.1 ± 0.9 3.92 ± 0.28 1.2 ± 0.1 2.84 ± 0.01 
G4 401.5 ± 1.1 1.0 ± 0.8 3.43 ± 0.09 1.4 ± 0.1 2.96 ± 0.01 
GH1 332.8 ± 1.0 1.4 ± 1.0 3.23 ± 0.06 1.4 ± 0.1 2.48 ± 0.00 
GH2 420.2 ± 0.9 0.9 ± 1.1 3.24 ± 0.10 1.3 ± 0.2 3.25 ± 0.01 
GH3 418.5 ± 0.8 1.0 ± 0.9 4.50 ± 0.07 0.8 ± 0.1 3.18 ± 0.01 
GE1 331.9 ± 1.1 1.0 ± 0.8 3.70 ± 0.07 1.0 ± 0.1 2.47 ± 0.01 
GE2 419.5 ± 0.7 0.6 ± 0.7 4.25 ± 0.17 0.8 ± 0.1 3.12 ± 0.01 
GE3 419.3 ± 0.5 0.9 ± 0.9 5.58 ± 0.09 0.7 ± 0.1 3.18 ± 0.00 
GHE1 420.5 ± 0.8 0.8 ± 0.9 5.11 ± 0.06 0.4 ± 0.1 3.18 ± 0.01 
GHE2 511.4 ± 0.7 0.6 ± 0.6 5.64 ± 0.12 0.3 ± 0.1 3.80 0.01 
G: Guar gum, GH: Guar gum + HPMC K15M, GE: Guar gum + Eudragit S100,  
GHE: Guar gum + HPMC K15M + Eudragit S100 
 
Table 4:The accelerated stability study test for the formula (GHE2) 
Test time Color  








Zero Time Pale green 511.4 ± 0.7 5.64 ± 0.12 0.3 ± 0.1 
1 month Pale green 510 ± 0.7 5.53 ± 0.05 0.3 ± 0.1 
2 months Pale green 510.3 ± 1.0 5.68 ± 0.18 0.2 ± 0.1 
3 months Pale green 509.6 ± 0.3 5.72 ± 0.12 0.3 ± 0.0 
 
